论文部分内容阅读
目的探讨辛伐他汀对急性脑梗死(ACI)患者血清白细胞介素6(IL-6)及C-反应蛋白(CRP)水平变化的影响。方法将ACI患者54例随机分为辛伐他汀组27例和常规治疗组27例,分别于治疗前及治疗4周后行血清IL-6(放射免疫分析法)及CRP(速率散射比浊法)检测。另选同期健康体检的27例作为对照组。结果 ACI组治疗前血清IL-6,CRP水平均明显高于对照组(均P<0.05)。辛伐他汀组治疗后血清IL-6,CRP水平均明显低于治疗前(均P<0.05),且低于常规治疗组(均P<0.05),差异具有显著性;但仍高于对照组(均P<0.05)。常规治疗组患者治疗后血清IL-6,CRP降低不明显(P>0.05)。结论 ACI患者应用辛伐他汀治疗使IL-6,CRP显著降低,有明显抗炎作用。
Objective To investigate the effects of simvastatin on the levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in patients with acute cerebral infarction (ACI). Methods 54 patients with ACI were randomly divided into simvastatin group (n = 27) and conventional treatment group (n = 27). Serum IL-6 (radioimmunoassay) and CRP . Another 27 cases of the same period of physical examination as a control group. Results The levels of serum IL-6 and CRP before treatment in ACI group were significantly higher than those in control group (all P <0.05). The levels of serum IL-6 and CRP in simvastatin group were significantly lower than those before treatment (all P <0.05), and were lower than those in routine treatment group (all P <0.05) (All P <0.05). The reduction of serum IL-6 and CRP was not obvious in the treatment group (P> 0.05). Conclusions The treatment with simvastatin in ACI patients significantly reduces the levels of IL-6 and CRP, and has obvious anti-inflammatory effects.